Back to top
more

Indivior (INDV)

(Real Time Quote from BATS)

$17.08 USD

17.08
38,333

+0.11 (0.65%)

Updated May 20, 2024 01:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Indivior (INDV) delivered earnings and revenue surprises of -2.63% and 5.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Indivior (INDV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Indivior PLC (INDV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Indivior PLC (INDV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia

by Zacks Equity Research

Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.

Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata

by Zacks Equity Research

The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.

Here's Why You Should Invest in Aldeyra (ALDX) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.

Zacks.com featured highlights Modine Manufacturing, Indivior and Interface

by Zacks Equity Research

Modine Manufacturing, Indivior and Interface have been highlighted in this Screen of The Week article.

Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat

by Zacks Equity Research

Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.

Santanu Roy headshot

3 Must-Buy Efficient Stocks to Strengthen Your Portfolio

by Santanu Roy

Invest in companies like Modine Manufacturing (MOD), Indivior (INDV) and Interface (TILE) that are powered by higher efficiency levels.

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

by Zacks Equity Research

Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.

Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates

by Zacks Equity Research

Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.

Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat

by Zacks Equity Research

Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.

Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates

by Zacks Equity Research

Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.

Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks

by Zacks Equity Research

Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.

Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down

by Zacks Equity Research

Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.

Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates

by Zacks Equity Research

Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.

Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Neurocrine (NBIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Indivior PLC (INDV) Loses -17.71% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Indivior PLC (INDV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Indivior PLC (INDV) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Indivior PLC (INDV) delivered earnings and revenue surprises of 13.33% and 2.26%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Supernus (SUPN) delivered earnings and revenue surprises of -323.08% and 8.74%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Indivior PLC (INDV) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Indivior PLC (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.